Despite keen interest in BAFF-R inhibition, rheumatologists favor BMS’ Sotyktu (deucravacitinib) as the leading therapy in development for Sjögren’s.EXTON, PA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- ...
EAET, the initial clinical trials of which took place in the 2000s, targets the past trauma and stress experienced by people having chronic pain conditions, but can worsen their symptoms. Some of ...